NCT03769402

Brief Summary

This study evaluates the effect of citric acid on bone surface of infrabony defects when used for 30 seconds at ph 1 and 50% concentration before the application of bovine derived xenograft to fill the defect, Bone Morphogenic protein 2 (BMP-2) marker was evaluated in 5 different days during the first month after surgery and clinical and radiographic parameters were reassessed after 6 months

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jan 2016

Typical duration for phase_4

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2018

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 6, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 7, 2018

Completed
Last Updated

December 7, 2018

Status Verified

December 1, 2018

Enrollment Period

2.3 years

First QC Date

December 6, 2018

Last Update Submit

December 6, 2018

Conditions

Outcome Measures

Primary Outcomes (5)

  • Bone Morphogenic protein 2

    The level of Bone morphogenic protein 2 was measured in the gingival crevicular fluid using a perio-paper then the marker level was determined using an Enzyme linked immunosorbent kit (ELISA kit)

    1 day

  • Bone Morphogenic protein 2

    The level of Bone morphogenic protein 2 was measured in the gingival crevicular fluid using a perio-paper then the marker level was determined using an Enzyme linked immunosorbent kit (ELISA kit)

    3 days

  • Bone Morphogenic protein 2

    The level of Bone morphogenic protein 2 was measured in the gingival crevicular fluid using a perio-paper then the marker level was determined using an Enzyme linked immunosorbent kit (ELISA kit)

    7 days

  • Bone Morphogenic protein 2

    The level of Bone morphogenic protein 2 was measured in the gingival crevicular fluid using a perio-paper then the marker level was determined using an Enzyme linked immunosorbent kit (ELISA kit)

    14 days

  • Bone Morphogenic protein 2

    The level of Bone morphogenic protein 2 was measured in the gingival crevicular fluid using a perio-paper then the marker level was determined using an Enzyme linked immunosorbent kit (ELISA kit)

    30 days

Secondary Outcomes (5)

  • Gingival Index

    6 months

  • Plaque index

    6 months

  • Probing depth

    6 months

  • Clinical attachment level

    6 months

  • Radiographic bone fill

    6 months

Study Arms (2)

Citric acid

ACTIVE COMPARATOR

Citric acid PH1 and concentration 50% was used for 30 seconds on bone surface before washing it off and filling the defect with xenograft

Drug: Citric acid

Control

PLACEBO COMPARATOR

Control test

Drug: Control Test

Interventions

Citric acid ph1, 50% concentration solution

Citric acid

Control group, xenograft was used to fill infrabony defects without treating bone surface

Also known as: Control
Control

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Both genders aged between 32-60 years.
  • Selected patient with a single site of:
  • Two walled or three walled infra-bony defect.
  • The bone defect should be at least 3 mm in depth from the crest of the alveolar bone to the base of the defect.
  • Pocket depth of more than or equal to 5 mm.
  • Clinical attachment loss equal or more than 3mm
  • Patients ready to comply with oral hygiene measures.

You may not qualify if:

  • Any systemic disease that contra-indicates periodontal surgery or may affect healing.
  • Smokers
  • Pregnant females
  • Drug abusers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Citric Acid

Intervention Hierarchy (Ancestors)

CitratesTricarboxylic AcidsAcids, AcyclicCarboxylic AcidsOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized clinical trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Teaching assistant

Study Record Dates

First Submitted

December 6, 2018

First Posted

December 7, 2018

Study Start

January 1, 2016

Primary Completion

May 1, 2018

Study Completion

November 1, 2018

Last Updated

December 7, 2018

Record last verified: 2018-12